[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367563-105":59,"doc-detail-367563-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","shaping-the-battlefield-egfr-and-kras-tumor-mutations-role-on-the-immune-microenvironment-and-immunotherapy-responses-in-lung-cancer","Shaping the battlefield: EGFR and KRAS tumor mutations’ role on the immune microenvironment and immunotherapy responses in lung cancer","","The two most common and mutually exclusive driver mutations in non-small cell lung cancer shape divergent immune tumor microenvironments. EGFR mutations are linked to non-inflamed microenvironments and poorer responses to current immunotherapies, whereas KRAS mutations associate with tobacco exposure, higher mutational burden, and immunologically more active tumors. Differences in outcomes are discussed through the tumor immune microenvironment, including T lymphocytes, other immune cell subsets, cancer-associated fibroblasts, immunomodulatory cytokines, and angiogenesis. The review summarizes evidence and highlights knowledge gaps to guide future investigation and clinical immunotherapy strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/shaping-the-battlefield-egfr-and-kras-tumor-mutations-role-on-the-immune-microenvironment-and-immunotherapy-responses-in-lung-cancer/367563/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/shaping-the-battlefield-egfr-and-kras-tumor-mutations-role-on-the-immune-microenvironment-and-immunotherapy-responses-in-lung-cancer/367563.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What distinguishes EGFR and KRAS driver mutations in non-small cell lung cancer?","Question",{"text":112,"@type":113},"EGFR and KRAS are mutually exclusive driver mutations. EGFR is typically linked to non-inflamed tumor microenvironments, while KRAS is associated with tobacco smoking, higher mutational burden, and more immunologically active tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do EGFR and KRAS mutations relate to immunotherapy outcomes?",{"text":117,"@type":113},"Current cancer immunotherapies have failed in many patients with EGFR mutations, whereas patients with KRAS mutations tend to have more favorable outcomes. The review attributes part of this difference to distinct tumor immune microenvironment features.",{"name":119,"@type":110,"acceptedAnswer":120},"Which components of the tumor immune microenvironment are highlighted as important in these cancers?",{"text":121,"@type":113},"Beyond T lymphocytes, the review highlights other immune cell types, cancer-associated fibroblasts, immunomodulatory cytokines, and angiogenesis as emerging players influencing immunotherapy responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367563,1790229321,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Cancer and Metastasis Reviews (2025) 44:56  \n[https://doi.org/10.1007/s10555-025-10272-4](https://doi.org/10.1007/s10555-025-10272-4)  \nShaping the battlefield: EGFR andKRAS tumor mutations’ role on the immune microenvironment and immunotherapy responsesin lung cancer  \nBassel Alsaed1,2 · Nina Bobik1,2 · Hanna Laitinen1,2 · Tanvi Nandikonda1,2 · Ilkka Ilonen2,3 · Heidi M. Haikala1,2,4  \nReceived: 20 December 2024 / Accepted: 2 June 2025 / Published online: 17 June 2025 © The Author(s) 2025  \nAbstract  \nThe two most common and mutually exclusive driver mutations in non-small cell lung cancer affect EGFR and KRAS oncogenes. While EGFR mutations typically arise in non-smokers and are correlated with non-inflamed tumor microenvironment, KRAS mutations are associated with tobacco smoking, high mutational burden, and immunologically more active tumors. Consequently, current cancer immunotherapies have failed in patients with EGFR mutations, while patients with KRAS mutations have more favorable outcomes. The distinctive properties of the tumor immune microenvironment can partly explain the differences in the treatment outcomes. Besides the undeniable role ofT lymphocytes, other immune cell types, cancer-associated fibroblasts, immunomodulatory cytokines, and angiogenesis are emerging as important players in these tumors. This article summarizes the current knowledge about the impact of EGFR versus KRAS mutations, among other mutations, on the tumor microenvironment and immunotherapy responses in lung cancer, highlighting the possible clinical implications for present and upcoming immunotherapy regiments, as well as emphasizing the gaps in the current knowledge that should be further investigated.  \nKeywords Lung cancer · Immunotherapy · Tumor microenvironment · EGFR · KRAS  \n1 Introduction  \nNon-small cell lung cancers (NSCLCs) account for approximately 85% of all lung cancers, with lung adenocarcinomasas the most predominant histological subtype. EGFR and KRAS are well-known oncogenes established as the most common driver mutations within these tumors [1] . The two mutations are mutually exclusive and show distinct incidence in relation to the ethnicity and smoking history of the patients. Furthermore, their differential responsiveness to  \n* Heidi M. Haikala [heidi.haikala@helsinki.fi](heidi.haikala@helsinki.fi)  \n1 Translational Immunology Research Program (TRIMM), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland  \n2 iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland  \n3 Department of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital & University of Helsinki, Helsinki, Finland  \n4 Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland  \ncurrently available immunotherapies underscore the importance of personalized treatment choices [2] . The underlying factors contributing to the immunotherapy responses in EGFR-and KRAS-mutated NSCLCs remain uncertain. Still, these effects are believed to be mediated by specific components within the tumor (immune) microenvironment (TME/ TIME) . This review outlines the current understanding of how EGFR, KRAS, and other key mutations influence immunotherapy responses and tumor immunology. Additionally, recent studies investigating the composition of the TME/ TIME in EGFR-versus KRAS-mutated NSCLC are summarized. By better understanding the intricacies of the TME/ TIME in these prevalent mutation types, we could further advance novel therapies targeting not only the tumor cells but also their malignant TME/TIME.  \n1.1 EGFR in lung cancer  \nEGFR is a transmembrane receptor tyrosine kinase (RTK) with an extracellular epidermal growth factor (EGF) binding domain, a transmembrane domain, and an intracellular signaling region. It modulates pivotal cellular processes such as proliferation, growth, and inhibition of apoptosis through  \nFig. 1 Schematic represent","cbCaifMtgwMDLA7r","https://ap.wps.com/l/cbCaifMtgwMDLA7r","pdf",2700840,18,"English","# Abstract\n# Keywords\n# Introduction\n## EGFR in lung cancer","[{\"question\":\"What distinguishes EGFR and KRAS driver mutations in non-small cell lung cancer?\",\"answer\":\"EGFR and KRAS are mutually exclusive driver mutations. EGFR is typically linked to non-inflamed tumor microenvironments, while KRAS is associated with tobacco smoking, higher mutational burden, and more immunologically active tumors.\"},{\"question\":\"How do EGFR and KRAS mutations relate to immunotherapy outcomes?\",\"answer\":\"Current cancer immunotherapies have failed in many patients with EGFR mutations, whereas patients with KRAS mutations tend to have more favorable outcomes. The review attributes part of this difference to distinct tumor immune microenvironment features.\"},{\"question\":\"Which components of the tumor immune microenvironment are highlighted as important in these cancers?\",\"answer\":\"Beyond T lymphocytes, the review highlights other immune cell types, cancer-associated fibroblasts, immunomodulatory cytokines, and angiogenesis as emerging players influencing immunotherapy responses.\"}]","Shaping the battlefield: EGFR and KRAS tumor mutations’ role on the immune microenvironment and immunotherapy responses in lung cancer | PDF",1790171391,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02ccc0b059431030eee9085426e54007.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c37fd39866367c47a882ec2c9530046.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44a128cf2c792bde3d1733d98aae4979.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5de5a25a384934ed74225d15c9423cb5.webp",980,1301]